![Case Study: AML Phase 1-2 Trial](https://www.precisionformedicine.com/hs-fs/hubfs/PFM%20-%202024%20New%20blog%20images/Case-Study-AML-Phase-1-2-1200x675.jpeg?width=396&height=224&name=Case-Study-AML-Phase-1-2-1200x675.jpeg)
![Anne, Kopko Avatar](https://www.precisionformedicine.com/hs-fs/hubfs/PfM%20Website/PfMxMarkentive/authors/Anne-Kopko-300x300.jpeg?width=100&height=100&name=Anne-Kopko-300x300.jpeg)
Anne Kopko
Anne Kopko is a Clinical Science Analytics & Insights Principal Scientist with fifteen years of professional oncology clinical research experience supporting Phase 1-3 clinical trials across a variety of therapeutic areas, including first-in-human, Phase 1-2 combination trials, dose escalation and expansion hematology and solid tumor studies. She plays a pivotal role in navigating the complex landscape of clinical data quality and supporting the cross-functional data cleaning process. She is a knowledgeable and collaborative partner with a passion to deliver quality data to her clients through a holistic, clinical sense data review approach.
-
Read: Case Study: AML Phase 1-2 Trial Case Study: AML Phase 1-2 Trial
Loading...
You've reach the end